Page last updated: 2024-12-10

1-(4-bromophenyl)-N-(3,4-dichlorophenyl)-5-oxo-3-pyrrolidinecarboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

The compound you've described, **1-(4-bromophenyl)-N-(3,4-dichlorophenyl)-5-oxo-3-pyrrolidinecarboxamide**, is a synthetic organic molecule with a complex structure. It's important to note that this compound doesn't have a widely recognized name or common use.

**Structure:**

The molecule consists of:

* A **pyrrolidine ring** (a 5-membered ring with one nitrogen atom)
* A **carboxamide group** attached to the pyrrolidine ring
* A **phenyl ring** (a 6-membered ring with alternating single and double bonds) substituted with a bromine atom at the 4-position, attached to the nitrogen of the carboxamide group
* Another **phenyl ring** substituted with chlorine atoms at the 3 and 4 positions, attached to the nitrogen of the carboxamide group

**Potential Importance for Research:**

Given the complex structure and presence of multiple functional groups, this compound could be of interest for various research areas. However, without further context or information, it's difficult to pinpoint its exact significance. Here are some possibilities:

* **Pharmaceutical Research:** The presence of phenyl rings and a carboxamide group could indicate potential activity as a drug candidate. The specific substituents on the phenyl rings might influence binding affinity and interactions with biological targets.
* **Materials Science:** The compound could exhibit interesting physical properties, potentially leading to its application in material development.
* **Chemical Synthesis:** The molecule could serve as a building block or intermediate in the synthesis of other compounds with desired properties.
* **Biological Activity Studies:** Research might be conducted to investigate the compound's effects on biological systems, such as enzymes, receptors, or cells.

**To understand the true importance of this compound, more information is needed, such as:**

* The research context (e.g., drug discovery, material science)
* The specific properties being investigated (e.g., biological activity, physical properties)
* The researchers involved and their publications

Without this additional information, it's impossible to provide a definitive answer to why this compound is important for research.

Cross-References

ID SourceID
PubMed CID3116961
CHEMBL ID1301129
CHEBI ID120529

Synonyms (20)

Synonym
MLS000526254 ,
smr000116728
1-(4-bromo-phenyl)-5-oxo-pyrrolidine-3-carboxylic acid (3,4-dichloro-phenyl)-amide
OPREA1_324695
OPREA1_654873
CHEBI:120529
AKOS000339612
MLS002535237
1-(4-bromophenyl)-n-(3,4-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide
HMS2496H22
CHEMBL1301129
cid_3116961
1-(4-bromophenyl)-n-(3,4-dichlorophenyl)-5-oxo-3-pyrrolidinecarboxamide
bdbm33640
1-(4-bromophenyl)-n-(3,4-dichlorophenyl)-5-keto-pyrrolidine-3-carboxamide
1-(4-bromophenyl)-n-(3,4-dichlorophenyl)-5-oxidanylidene-pyrrolidine-3-carboxamide
AKOS024284137
SR-01000358385-1
sr-01000358385
Q27208382
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrrolidinesAny of a class of heterocyclic amines having a saturated five-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CruzipainTrypanosoma cruziPotency19.95260.002014.677939.8107AID1476
acid sphingomyelinaseHomo sapiens (human)Potency70.794614.125424.061339.8107AID504937
phosphopantetheinyl transferaseBacillus subtilisPotency35.48130.141337.9142100.0000AID1490
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686979
Smad3Homo sapiens (human)Potency22.38720.00527.809829.0929AID588855
IDH1Homo sapiens (human)Potency35.48130.005210.865235.4813AID686970
importin subunit beta-1 isoform 1Homo sapiens (human)Potency16.36015.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency16.36015.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency16.36015.804816.996225.9290AID540253
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency35.48130.00798.23321,122.0200AID2546; AID2551
survival motor neuron protein isoform dHomo sapiens (human)Potency14.12540.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency22.38720.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
prothrombinHomo sapiens (human)IC50 (µMol)50.00000.00103.317014.6895AID1215
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
streptokinase A precursorStreptococcus pyogenes M1 GASEC50 (µMol)12.31800.06008.9128130.5170AID1902; AID1914
Estrogen receptorRattus norvegicus (Norway rat)EC50 (µMol)20.13400.006022.3670130.5170AID1914
Estrogen receptor betaRattus norvegicus (Norway rat)EC50 (µMol)20.13400.006022.3670130.5170AID1914
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]